Omega-3

Dietary fatty acids are highlighted as a potential intervention for the neurological disease.

The ODS recognizes DHA's role in reducing preterm birth risk, citing several studies and reports.

Epax has announced the launch of what they say is the first commercially available very long chain polyunsaturated fatty acid (VLC-PUFA), called Epax Evolve 05.

The Longevity Nutrient, published by Simon & Schuster, and written by Stephanie Venn-Watson, DVM, MPH is now available for purchase online and wherever books are sold.

The study examined various risk factors, such as blood pressure and diabetes, in predicting cardiovascular disease.

Women-led omega-3 research advances wellness for all women’s life stages.

The new technology, plus a new algal variation, will be introduced at Expo West 2025.

This study builds on previous animal research that found the lipid emulsion made from Ahiflower was associated with significantly lower inflammation, improved insulin sensitivity, and improved gut microbiota, compared to that of soybean oil or fish oil.

The study compared muscle recovery after injury in rats with and without fish oil supplementation in their diets.

Recent study evaluated the association between plasma omega-3 levels and risk of heart failure

The algal EPA+DHA ingredient expands on the company's existing algal omega-3 portfolio which was DHA only.

CoreFX's showcased its recently announced CoreNhanced optimized delivery platform.

The Global Organization for EPA and DHA Omega-3s’ vice president of regulatory and scientific affairs talks about recent class actions and why they are without merit.

At SupplySide West 2024, Solutex will exhibit product offerings, as well as celebrate their 20th anniversary.

According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.

Results showed that both doses of krill oil significantly reduced TEWL, and increased hydration as well as elasticity compared to placebo.

SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.

The Canadian companies have joined forces to create more cost-effective and bioavailable fortification of plant-based omega-3s.

A recently published study found that Ahiflower oil from the seeds of Buglossoides arvensis may improve plasma eicosapentaenoic acid (EPA) levels.

A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.

The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.

Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.

According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.

The $75 million facility expansion allows the company to double its output of the triglyceride form of marine omega-3s EPA and DHA and certified vegan EPA & DHA algal oils.

The researchers concluded that fish oil supplementation by healthy people may actually put them at risk of developing atrial fibrillation and stroke, while offering a benefit to those diagnosed with cardiovascular disease by reducing their risk of experiencing major adverse cardiovascular events.